Literature DB >> 19453946

Normal protein composition of synapses in Ts65Dn mice: a mouse model of Down syndrome.

Fabian Fernandez1, Jonathan C Trinidad, Martina Blank, Dong-Dong Feng, Alma L Burlingame, Craig C Garner.   

Abstract

Down syndrome (DS) is the most prevalent form of intellectual disability caused by the triplication of approximately 230 genes on chromosome 21. Recent data in Ts65Dn mice, the foremost mouse model of DS, strongly suggest that cognitive impairment in individuals with DS is a consequence of reduced synaptic plasticity because of chronic over-inhibition. It remains unclear however whether changes in plasticity are tied to global molecular changes at synapses, or are due to regional changes in the functional properties of synaptic circuits. One interesting framework for evaluating the activity state of the DS brain comes from in vitro studies showing that chronic pharmacological silencing of neuronal excitability orchestrates stereotyped changes in the protein composition of synaptic junctions. In the present study, we use proteomic strategies to evaluate whether synapses from the Ts65Dn cerebrum carry signatures characteristic of inactive cortical neurons. Our data reveal that synaptic junctions do not exhibit overt alterations in protein composition. Only modest changes in the levels of synaptic proteins and in their phosphorylation are observed. This suggests that subtle changes in the functional properties of specific synaptic circuits rather than large-scale homeostatic shifts in the expression of synaptic molecules contribute to cognitive impairment in people with DS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453946      PMCID: PMC2735138          DOI: 10.1111/j.1471-4159.2009.06110.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  70 in total

Review 1.  The postsynaptic architecture of excitatory synapses: a more quantitative view.

Authors:  Morgan Sheng; Casper C Hoogenraad
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

2.  Quantitative analysis of synaptic phosphorylation and protein expression.

Authors:  Jonathan C Trinidad; Agnes Thalhammer; Christian G Specht; Aenoch J Lynn; Peter R Baker; Ralf Schoepfer; Alma L Burlingame
Journal:  Mol Cell Proteomics       Date:  2007-12-03       Impact factor: 5.911

Review 3.  Synaptic trafficking of glutamate receptors by MAGUK scaffolding proteins.

Authors:  Guillermo M Elias; Roger A Nicoll
Journal:  Trends Cell Biol       Date:  2007-07-20       Impact factor: 20.808

4.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Wade Morishita; Elizabeth Zuniga; James Nguyen; Martina Blank; Robert C Malenka; Craig C Garner
Journal:  Nat Neurosci       Date:  2007-02-25       Impact factor: 24.884

5.  The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome.

Authors:  Jesse E Hanson; Martina Blank; Ricardo A Valenzuela; Craig C Garner; Daniel V Madison
Journal:  J Physiol       Date:  2006-12-07       Impact factor: 5.182

6.  Over-inhibition: a model for developmental intellectual disability.

Authors:  Fabian Fernandez; Craig C Garner
Journal:  Trends Neurosci       Date:  2007-09-06       Impact factor: 13.837

7.  Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn.

Authors:  G Pollonini; V Gao; A Rabe; S Palminiello; G Albertini; C M Alberini
Journal:  Neuroscience       Date:  2008-07-25       Impact factor: 3.590

8.  The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting.

Authors:  Georgina M Aldridge; David M Podrebarac; William T Greenough; Ivan Jeanne Weiler
Journal:  J Neurosci Methods       Date:  2008-05-15       Impact factor: 2.390

9.  Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome.

Authors:  Pavel V Belichenko; Alexander M Kleschevnikov; Eliezer Masliah; Chengbiao Wu; Ryoko Takimoto-Kimura; Ahmad Salehi; William C Mobley
Journal:  J Comp Neurol       Date:  2009-02-01       Impact factor: 3.215

Review 10.  Neuroligins and neurexins link synaptic function to cognitive disease.

Authors:  Thomas C Südhof
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

View more
  11 in total

1.  Regulation of protein levels in subcellular domains through mRNA transport and localized translation.

Authors:  Dianna E Willis; Jeffery L Twiss
Journal:  Mol Cell Proteomics       Date:  2010-02-18       Impact factor: 5.911

2.  Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression.

Authors:  Jie Lu; Monika Mccarter; Gewei Lian; Giuseppe Esposito; Elena Capoccia; Laurent C Delli-Bovi; Jonathan Hecht; Volney Sheen
Journal:  Hum Mol Genet       Date:  2016-02-23       Impact factor: 6.150

3.  Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.

Authors:  Guido N Vacano; David S Gibson; Abdullah Arif Turjoman; Jeremy W Gawryluk; Jonathan D Geiger; Mark Duncan; David Patterson
Journal:  Neurobiol Aging       Date:  2017-11-26       Impact factor: 4.673

4.  Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.

Authors:  Jonah J Scott-McKean; Alberto C S Costa
Journal:  Learn Mem       Date:  2011-11-18       Impact factor: 2.460

Review 5.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

6.  Altered synaptic marker abundance in the hippocampal stratum oriens of Ts65Dn mice is associated with exuberant expression of versican.

Authors:  Matthew D Howell; Paul E Gottschall
Journal:  ASN Neuro       Date:  2012-02-08       Impact factor: 4.146

Review 7.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

8.  DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.

Authors:  Ilario De Toma; Mireia Ortega; Patrick Aloy; Eduard Sabidó; Mara Dierssen
Journal:  Front Mol Neurosci       Date:  2019-11-15       Impact factor: 5.639

Review 9.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

10.  Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Macarena Gómez de Salazar; Cristina Grau; Francisco Ciruela; Xavier Altafaj
Journal:  Front Mol Neurosci       Date:  2018-07-25       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.